NCT06209580View on ClinicalTrials.gov

AMT-253 in Patients With Advanced Solid Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Malignant MelanomaAdvanced Solid Tumors
Interventions
DRUG

AMT-253 for injection

Administered intravenously

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Multitude Therapeutics Inc.

INDUSTRY